JCO Precision Oncology Conversations

American Society of Clinical Oncology (ASCO)•ascopubs.org

JCO Precision Oncology Conversations podcasts features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they examine groundbreaking research in the world of precision oncology and learn how these advancements are redefining treatment protocols. The year's fellows summarize the top JCO Precision Oncology articles in the series, JCO PO Article Insights.

Last refreshed: June 24th, 2026 at 5:08 PM

Follow on

Apple Podcasts

Spotify

RSS

Podcasts are better in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

Pertuzumab + Trastuzumab in Lung Cancer with ERBB2 Alterations

JCO PO author Dr. Apar K. Ganti shares insights into his JCO PO article, "Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study." Host Dr. Rafeh Naqash and Dr. Ganti discuss clinical decision-making regarding biopsy; HER2 amplification, mutation, and targeted therapy; drug combinations; and aspects of the TAPUR and DESTINY-Lung studies. Click here to read the article! TRANSCRIPT Dr. ...

Aug 16, 2023•28 min

MMR-P Colorectal Cancer in Lynch Syndrome

JCO PO author Dr. Alicia Latham shares insights into her JCO PO article, "Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome." Host Dr. Rafeh Naqash and Dr. Latham discuss microsatellite instability-high status as well as familial risk and testing. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations , where we bring you engaging conversations with authors of clini...

Jul 19, 2023•26 min

Real-World NTRK Fusions and TRK Inhibitors in Veterans

JCO PO authors Dr. Michael J. Kelley and Dr. Katherine I. Zhou share insights into their JCO PO article, "Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans." Host Dr. Rafeh Naqash, Dr. Kelley, and Dr. Zhou discuss the robust Veterans Affairs (VA) National Precision Oncology Program (NPOP), accurate identification of gene fusions, and toxicities landscape of TRK inhibitors. Click here to read the article!...

Jun 21, 2023•28 min

Larotrectinib for TRK Fusion - Positive Lung Cancer

JCO PO author Alexander E. Drilon, MD, shares insights into his article, "Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers" and the article's findings of the activity of larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions. Host Dr. Rafeh Naqash and Dr. Drilon discuss drug development, testing for fusions, resistance mechanisms, and cancer metastases. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqa...

May 17, 2023•29 min

ctDNA for Recurrence Prediction in Esophagogastric Cancers

JCO PO author Dr. Brandon Huffman shares insights into his JCO PO article, "Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers" and discusses the article's findings of ctDNA levels in the preoperative, postoperative, and surveillance settings in patients with EGC. Host Dr. Rafeh Naqash and Dr. Huffman discuss ctDNA assessments, treatment paradigms and interventions, and tumor-informed assays. TRANSCRIPT Dr. Abdul Rafeh Naqash: Hello, a...

Apr 19, 2023•29 min

KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors

JCO PO author Dr. Mohamed Salem shares insights into his JCO PO article, "Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers" and the article's findings of a large-scale, pan-cancer genomic characterization of KRASG12C. Host Dr. Rafeh Naqash and Dr. Salem discuss KRASG12C mutation, KRASG12C -mutated tumors and comutation with STK11 and KEAP1. Click here to read the article! TRANSCRIPT Dr. Abdul Rafeh Naqash: Hello and ...

Mar 15, 2023•23 min

Universal Genetic Germline Testing in Solid Tumor Cancer Patients

JCO PO authors Dr. Edward Esplin and Professor Heather Hampel share insights into their JCO PO commentary, "Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer" and discuss practical implications of testing for patients, geneticists, and clinicians. Host Dr. Rafeh Naqash, Dr. Esplin, and Professor Hampel discuss standard of care guidelines, insurance coverage, and benefits of testing. Click here to read the article! TRANSCRIPT Dr. Abdul Rafeh Na...

Feb 15, 2023•34 min

Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma, with Dr. Shilpa Gupta

JCO PO author Dr. Shilpa Gupta, MD, Associate Professor of Medicine at the Cleveland Clinic and GU Medical Oncology Director, shares analysis on outcomes in real-world settings for metastatic urothelial carcinoma (mUC) patients. Host Dr. Rafeh Naqash and Dr. Gupta discuss the utility of tumor mutational burden (TMB) to determine treatment, and mUC patient response from immune checkpoint inhibitors (ICPI) as compared with carboplatin. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: H...

Jan 18, 2023•23 min

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart

JCO PO author Dr. Mark Stewart, PhD, Vice President, Science Policy at Friends of Cancer Research, shares analysis on clinical trials and the association between CT-DNA and outcomes in lung cancer. Host Dr. Rafeh Naqash and Dr. Stewart discuss dataset metrics, identification of biomarkers, timepoints, and checkpoint inhibitors, development of new medicines, and novel technologies measuring CT-DNA. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: Welcome to ASCO's JCO Precision Oncolo...

Dec 21, 2022•26 min

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan

JCO PO author Dr. Mark Yarchoan, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, shares research on the four distinct subsets of biliary tract cancers (BTCs) and their varying immune responses and mutations. Dr. Naqash and Dr. Yarchoan discuss the article's study of intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma, and gallbladder cancer. Click here to read the article! Dr. Naqash: Welcome to ASCO's JCO Precision Oncology Conversations where we bring you the...

Nov 16, 2022•22 min

Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger

In this JCO Precision Oncology Conversations podcast, JCO PO author Dr. Thanh Dellinger of City of Hope National Medical Center shares insights into the research published in her article, "Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer." Podcast host Dr. Abdul Rafeh Naqash talks with Dr. Dellinger about hyperthermic intraperitoneal chemotherapy (HIPEC) and the various challenges of the treatment of epithelial ovarian canc...

Oct 19, 2022•22 min

Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford

In this introductory episode of the JCO Precision Oncology Conversations podcast, host Dr. Abdul Rafeh Naqash, MD, from the University of Oklahoma Stephenson Cancer Center, speaks with JCO Precision Oncology's founding Editor in Chief, Dr. James Ford, MD, of Stanford University. Dr. Naqash and Dr. Ford discuss how JCO Precision Oncology (JCO PO) started as a journal and how it has progressed since its launch in 2017. Dr. Ford dives into numerous JCO PO areas of interest, including liquid biopsy,...

Sep 21, 2022•20 min

← Prev

Hosted on Libsyn

For the best experience, listen in Metacast app for iOS or Android